Skip to Main Content

If you step back and look at the state of biotech three-quarters into the year, here is what you see: an industry that is humming along, outpacing the S&P by a healthy margin, setting IPO records, and showering startups with cash. As for everyone’s worst fears — President’s Trump’s drug-pricing rants blowing up everything, for instance — they haven’t come to pass.

That’s all great. But what’s the view from the perspective of individual biotech companies?


Last January, I compiled a list of “burning questions” facing certain biotechs heading into 2018. Revisiting the list eight months later reveals a mixed bag of triumphs, pratfalls, and some continuing uncertainty. Here’s a look at my earlier questions — and updated answers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.